Fairfield, Bush & Co’s Juno Therapeutics, Inc. JUNO Stock Holding History

Fairfield, Bush & Co’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-18,075	Closed	-$826K	–	200
2017 Q4	$826K	Sell	18,075 -1,400	-7%	-$69.8K	0.23%	77
2017 Q3	$874K	Sell	19,475 -2,000	-9%	-$68.2K	0.27%	69
2017 Q2	$642K	Hold	21,475	–	–	0.21%	78
2017 Q1	$477K	Buy	21,475 +9,900	+86%	+$212K	0.15%	101
2016 Q4	$218K	Sell	11,575 -175	-1%	-$4.28K	0.07%	139
2016 Q3	$353K	Buy	11,750 +1,050	+10%	+$32.7K	0.11%	115
2016 Q2	$411K	Buy	10,700 +4,750	+80%	+$197K	0.14%	102
2016 Q1	$227K	Buy	+5,950	New	+$207K	0.08%	122

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Fairfield, Bush & Co's JUNO Position: Q1 2018 in Review

Fairfield, Bush & Co sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 18,075 shares — an estimated $826K sold.

Fairfield, Bush & Co first reported a position in JUNO in Q1 2016 and held it in 8 quarters. The position peaked at $874K in Q3 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Fairfield, Bush & Co reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Fairfield, Bush & Co sold 18,075 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $826K.
Fairfield, Bush & Co first reported a position in Juno Therapeutics, Inc. in Q1 2016 and held it in 8 quarters.
Fairfield, Bush & Co's Juno Therapeutics, Inc. position peaked at $874K in Q3 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Fairfield, Bush & Co's 13F filing for Q1 2018, filed 9 May 2018.